A team composed of our partner Gabriele Prenna and associate Giovanni Gerbini assisted Cassiopea S.p.A., a pharmaceutical company focused on biotechnology and listed on the SIX Swiss Exchange, on recently completed share capital increase.

Company’s shareholders were offered 750.000 newly issued ordinary shares with nominal value of € 1.00 and subscription price of € 31.00 each.

The offer period started on 3 June and ended on 17 June with the full subscription of the new capital for a total value of € 23. 250.000 including share premium, resulting in the capital increase up to the nominal value of € 10.750.000.